PMID- 37996337
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20240130
IS  - 2013-2514 (Electronic)
IS  - 2013-2514 (Linking)
VI  - 43
IP  - 5
DP  - 2023 Sep-Oct
TI  - Association of the rs5186 polymorphism of the AGTR1 gene with decreased eGFR in 
      patients with type 2 diabetes from Mexico City.
PG  - 546-561
LID - S2013-2514(23)00163-3 [pii]
LID - 10.1016/j.nefroe.2022.06.010 [doi]
AB  - BACKGROUND: Early biomarkers search for Diabetic Kidney Disease (DKD) in patients 
      with Type 2 Diabetes Mellitus (T2DM), as genetic markers to identify vulnerable 
      carriers of the disease even before Glomerular Filtration Rate (GFR) decline or 
      microalbuminuria development, has been relevant during the last few years. The 
      rs5186 (A116C) polymorphism of the Angiotensin II Receptor Type I gene (AGTR1), 
      has been associated to multiple effects of renal injury risk, commonly detected 
      in patients with Diabetes Mellitus (DM). It has been described that rs5186 could 
      have an effect in stability proteins that assemble Angiotensin II Receptor Type I 
      (AT1), modifying its action, which is why it should be considered as a risk 
      factor for Chronic Kidney Disease (CKD), characterized by a GFR progressive 
      reduction. Even though, the association between rs5186 AGTR1 gene polymorphism 
      and DKD in patients with T2DM has been controversial, inconclusive, and even 
      absent. This disputable issue might be as a result of association studies in 
      which many and varied clinical phenotypes included are contemplated as CKD 
      inductors and enhancers. Although, the sample sizes studied in patients with T2DM 
      are undersized and did not have a strict inclusion criteria, lacking of 
      biochemical markers or KDOQI classification, which have hindered its examination. 
      OBJECTIVE: The aim of our study was to establish an association between rs5186 
      AGTR1 gene polymorphism and GFR depletion, assessed as a risk factor to DKD 
      development in patients with T2DM. METHODS: We analyzed 297 not related patients 
      with T2DM, divided into 221 controls (KDOQI 1) and 76 cases (KDOQI 2). Arterial 
      pressure, anthropometric and biochemical parameters were measured. rs5186 of 
      AGTR1 genotyping was performed by TaqMan assay real-time PCR method. Allele and 
      genotype frequencies, and Hardy-Weinberg equilibrium were measured. Normality 
      test for data distribution was analyzed by Shapiro-Wilk test, variable comparison 
      by Student's t-test for continuous variables, and Chi-squared test for 
      categorical variables; ANOVA test was used for mean comparison of more than two 
      groups. Effect of rs5186 to DKD was estimated by multiple heritability adjustment 
      models for risk variables of DKD. Statistical significance was indicated by 
      p<0.05. Data was analyzed using Statistical Package STATA v11 software. RESULTS: 
      Dominant and Over-dominant models showed a likelihood ratio to GFR depletion of 
      1.89 (1.05-3.39, p=0.031) and 2.01 (1.08-3.73, p=0.023) in patients with T2DM. 
      Risk factor increased to 2.54 (1.10-5.89) in women in Over-dominant model. 
      CONCLUSION: In clinical practice, most of nephropathies progress at a slow pace 
      into a total breakdown of renal function, even asymptomatic. This is the first 
      study, reporting that rs5186 polymorphism of AGTR1 gene contribution to GFR 
      depletion, and this could be evaluated as a predisposing factor for DKD in 
      patients with T2DM.
CI  - Copyright (c) 2022 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, 
      S.L.U. All rights reserved.
FAU - Figueroa, Manuel Alejandro Contreras
AU  - Figueroa MAC
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Seccion de Estudios de Posgrado e Investigacion, Escuela Superior 
      de Medicina del Instituto Politecnico Nacional, Ciudad de Mexico, Mexico.
FAU - Lujambio, Irene Mendoza
AU  - Lujambio IM
AD  - Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina del 
      Instituto Politecnico Nacional, Ciudad de Mexico, Mexico.
FAU - Gutierrez, Teresa Alvarado
AU  - Gutierrez TA
AD  - Coordinacion Clinica de Educacion e Investigacion en Salud de la Unidad de 
      Medicina Familiar 31, Instituto Mexicano del Seguro Social, Delegacion sur, 
      Ciudad de Mexico, Mexico.
FAU - Hernandez, Maria Fernanda Perez
AU  - Hernandez MFP
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Seccion de Estudios de Posgrado e Investigacion, Escuela Superior 
      de Medicina del Instituto Politecnico Nacional, Ciudad de Mexico, Mexico; Red de 
      Medicina Para la Educacion, el Desarrollo y la Investigacion Cientifica de 
      Iztacala. MEDICI, Facultad de Estudios Superiores Iztacala, UNAM, Estado de 
      Mexico, Mexico.
FAU - Ramirez, Evelyn Yazmin Estrada
AU  - Ramirez EYE
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Departamento de Nefrologia del Hospital de Especialidades "Dr. 
      Antonio Fraga Mouret", CMN La Raza, IMSS, Ciudad de Mexico, Mexico.
FAU - Guzman, Dominga Jimenez
AU  - Guzman DJ
AD  - Departamento de Nefrologia del Hospital de Especialidades "Dr. Bernardo 
      Sepulveda" CMN Siglo XXI, IMSS, Ciudad de Mexico, Mexico; Jefatura de la Unidad 
      de Consulta Externa de la UMAE, Hospital de Alta Especialidad Medica "Dr. 
      Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de Mexico, 
      Mexico.
FAU - Sanchez, Maria Fernanda Lucas
AU  - Sanchez MFL
AD  - Secretaria de Ensenanza Clinica, Internado y Servicio Social. Facultad de 
      Medicina UNAM, Ciudad de Mexico, Mexico; Becaria de la Direccion General de 
      Calidad y Educacion en Salud, Secretaria de Salud, Mexico.
FAU - Morales, Hannia Fernanda Gonzalez
AU  - Morales HFG
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Red de Medicina Para la Educacion, el Desarrollo y la 
      Investigacion Cientifica de Iztacala. MEDICI, Facultad de Estudios Superiores 
      Iztacala, UNAM, Estado de Mexico, Mexico.
FAU - Samudio, Hector Jaime Gomez
AU  - Samudio HJG
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico.
FAU - Sanchez, Fernando Suarez
AU  - Sanchez FS
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico.
FAU - Flores, Margarita Diaz
AU  - Flores MD
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico.
FAU - Zamarripa, Carlos Alberto Jimenez
AU  - Zamarripa CAJ
AD  - Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina del 
      Instituto Politecnico Nacional, Ciudad de Mexico, Mexico.
FAU - Mendoza, Claudia Camelia Calzada
AU  - Mendoza CCC
AD  - Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina del 
      Instituto Politecnico Nacional, Ciudad de Mexico, Mexico.
FAU - Hernandez, Maria Esther Ocharan
AU  - Hernandez MEO
AD  - Seccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina del 
      Instituto Politecnico Nacional, Ciudad de Mexico, Mexico.
FAU - Velazquez, Cora Mariana Orozco
AU  - Velazquez CMO
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Secretaria de Ensenanza Clinica, Internado y Servicio Social. 
      Facultad de Medicina UNAM, Ciudad de Mexico, Mexico.
FAU - Flores, Mariana Soto
AU  - Flores MS
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Departamento de Formacion Integral e Institucional, Escuela 
      Nacional de Medicina y Homeopatia, Instituto Politecnico Nacional, Ciudad de 
      Mexico, Mexico.
FAU - Orozco, Daniela Vicenta Hernandez
AU  - Orozco DVH
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico; Departamento de Formacion Integral e Institucional, Escuela 
      Nacional de Medicina y Homeopatia, Instituto Politecnico Nacional, Ciudad de 
      Mexico, Mexico.
FAU - Moreno, Gabriela Yanet Cortes
AU  - Moreno GYC
AD  - Coordinacion Nacional de Investigacion, Subdireccion de Servicios de salud de 
      Petroleos Mexicanos, PEMEX, Ciudad de Mexico, Mexico.
FAU - Cruz, Miguel
AU  - Cruz M
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico.
FAU - de Jesus Peralta Romero, Jose
AU  - de Jesus Peralta Romero J
AD  - Unidad de Investigacion Medica en Bioquimica, Unidad Medica de Alta Especialidad 
      "Dr. Bernardo Sepulveda", Centro Medico Nacional Siglo XXI, IMSS, Ciudad de 
      Mexico, Mexico. Electronic address: drjperalta@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20231122
PL  - Spain
TA  - Nefrologia (Engl Ed)
JT  - Nefrologia
JID - 101778581
RN  - 0 (Biomarkers)
RN  - 0 (AGTR1 protein, human)
RN  - 0 (Receptor, Angiotensin, Type 1)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Diabetes Mellitus, Type 2/complications/genetics
MH  - Mexico
MH  - Polymorphism, Genetic
MH  - Risk Factors
MH  - *Renal Insufficiency, Chronic/complications
MH  - Biomarkers
MH  - Receptor, Angiotensin, Type 1/genetics
OTO - NOTNLM
OT  - Angiotensin type 1 receptor
OT  - Diabetes mellitus tipo 2
OT  - Diabetes mellitus type 2
OT  - Diabetic nephropathies
OT  - Glomerular filtration rate
OT  - Nefropatia diabetica
OT  - Polimorfismo de un solo nucleotido
OT  - Receptor de angiotensina Tipo 1
OT  - Single nucleotide polymorphism
OT  - Tasa de filtracion glomerular
EDAT- 2023/11/24 00:42
MHDA- 2023/12/04 12:43
CRDT- 2023/11/23 22:02
PHST- 2021/09/08 00:00 [received]
PHST- 2022/06/10 00:00 [revised]
PHST- 2022/06/29 00:00 [accepted]
PHST- 2023/12/04 12:43 [medline]
PHST- 2023/11/24 00:42 [pubmed]
PHST- 2023/11/23 22:02 [entrez]
AID - S2013-2514(23)00163-3 [pii]
AID - 10.1016/j.nefroe.2022.06.010 [doi]
PST - ppublish
SO  - Nefrologia (Engl Ed). 2023 Sep-Oct;43(5):546-561. doi: 
      10.1016/j.nefroe.2022.06.010. Epub 2023 Nov 22.